Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Altman Z2-Score: 16.43 (As of Jul. 08, 2026) — Near Median


SHSE:600276 Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
86 GF Score
Price ¥54.01
GF Value ¥60.63
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Altman Z2-Score?

Jiangsu Hengrui Pharmaceuticals Co SHSE:600276 -2.44% 86 Altman Z2-Score is 16.43 as of Jul. 08, 2026, which is 4% below its 10-year median of 17.17. GuruFocus rates SHSE:600276 with a GF Score™ of 86/100 and a GF Value™ of ¥60.63 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 996 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 94.98% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Jiangsu Hengrui Pharmaceuticals Co has a Altman Z2-Score of 16.43, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score or its related term are showing as below:

SHSE:600276' s Altman Z2-Score Range Over the Past 10 Years
Min: 14.38   Med: 17.17   Max: 23.23
Current: 16.43

During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest Altman Z2-Score was 23.23. The lowest was 14.38. And the median was 17.17.


Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Jiangsu Hengrui Pharmaceuticals Co Altman Z2-Score Related Terms


Jiangsu Hengrui Pharmaceuticals Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Altman Z2-Score Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.09 16.85 22.61 19.13 14.92

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.64 23.23 14.38 14.92 16.43

SHSE:600276 vs ZTS, UTHR: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score falls into.


SHSE:600276
86GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.6509+3.26*0.5955+6.72*0.1289+1.05*8.9028
=16.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ¥71,294 Mil.
Total Current Assets was ¥52,044 Mil.
Total Current Liabilities was ¥5,637 Mil.
Retained Earnings was ¥42,456 Mil.
Pre-Tax Income was 2556.862 + 2295.618 + 1361.074 + 2975.33 = ¥9,189 Mil.
Interest Expense was -0.448 + -1.996 + -0.69 + -0.739 = ¥-4 Mil.
Total Liabilities was ¥7,147 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(52044.195 - 5636.724)/71293.862
=0.6509

X2=Retained Earnings/Total Assets
=42455.623/71293.862
=0.5955

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(9188.884 - -3.873)/71293.862
=0.1289

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(63626.264 - 0)/7146.776
=8.9028

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Jiangsu Hengrui Pharmaceuticals Co has a Altman Z2-Score of 16.43 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 16.43 mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Altman Z2-Score of 16.43 as of Jul. 08, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is near median its historical median of 17.17. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score has ranged from 14.38 to 23.23. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #50 out of 996 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score too high?
Jiangsu Hengrui Pharmaceuticals Co's current Altman Z2-Score of 16.43 is near median its 10-year median of 17.17. Over the past 10 years, this metric has ranged from a low of 14.38 to a high of 23.23. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Jiangsu Hengrui Pharmaceuticals Co's value of 16.43 is 325.1% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #50 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #50 out of 996 companies for Altman Z2-Score. This places Jiangsu Hengrui Pharmaceuticals Co in the top 5% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.87. Jiangsu Hengrui Pharmaceuticals Co's value of 16.43 is 325.1% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Altman Z2-Score has ranged from 14.38 to 23.23 over the past decade. While the company's 10-year median is 17.17 vs. the industry median of 3.87, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Altman Z2-Score of 16.43 is 325.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Altman Z2-Score is 16.43, which is near median its own 10-year median of 17.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.63, compared to a current price of ¥54.01 — trading 10.9% below its estimated fair value. The current Altman Z2-Score is 16.43, which is near median its 10-year median of 17.17 and 325.1% above the Drug Manufacturers industry median of 3.87. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Altman Z2-Score is 16.43 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥54.01 is trading 10.9% below its estimated GF Value™ of ¥60.63. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for SHSE:600276:

  • Altman Z2-Score: 16.43 (near median its 10-year median of 17.17)
  • GF Value™: ¥60.63 vs. price of ¥54.01 (10.9% below fair value)
  • GF Score™: 86/100 with 1 warning sign
  • Industry Position: 325.1% above the Drug Manufacturers median (#50 of 996)

No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
86GF Score

Get the complete analysis for SHSE:600276

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥54.01
Price
¥60.63
GF Value